FDA Approves First New Non-Opiod Painkiller in Decades
Journavx is designed to eliminate the risks of addiction and overdose associated with medications like Vicodin and OxyContin.
Vertex Pharmaceuticals Stock Jumps After FDA Approval for New Non-Opioid Painkiller
Journavx is the first and only approved non-opioid oral painkiller and the first new class of pain medicine approved in more ...
These Stocks Are Moving the Most Today: Apple, Intel, Chevron, Visa, Deckers, Atlassian, Vertex, and More
Apple stock rises after the tech giant posts better-than-expected earnings and guides for solid growth, while Intel’s ...
Vertex Pharmaceuticals stock is soaring. The FDA just approved its potentially game-changing pain treatment.
Shares of Vertex Pharmaceuticals Inc. surged ahead of Friday’s market open after the Food and Drug Administration approved ...
US FDA approves Vertex's non-opioid painkiller
The U.S. Food and Drug Administration has approved Vertex Pharmaceuticals' drug to treat acute pain, the health regulator ...
Vertex Pharmaceuticals Shares Gain After FDA Approves Non-Opioid Pain Drug
Shares of Vertex Pharmaceuticals rose after Journavx, the company’s oral non-opioid pain medication, received Food and Drug ...
Vertex Pharmaceuticals Incorporated Investigation Ongoing: Contact Levi & Korsinsky About Potential Securities Fraud Allegations - VRTX
NEW YORK, NY / ACCESS Newswire / January 31, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Vertex ...
Vertex Pharmaceuticals price target lowered to $320 from $325 at Baird
Baird lowered the firm’s price target on Vertex Pharmaceuticals (VRTX) to $320 from $325 and keeps an Underperform rating on the shares. The ...
FDA approves Vertex’s acute pain treatment Journavx
The US Food and Drug Administration (FDA) has approved Vertex Pharmaceuticals’ oral Journavx (suzetrigine) to treat adults ...
Vertex Announces CASGEVY® Reimbursement Agreement for the Treatment of Sickle Cell Disease in England
Vertex Pharmaceuticals (Nasdaq: VRTX) announced today a reimbursement agreement with NHS England for eligible sickle cell ...